announcements & circulars-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

investors

information disclosure

listing documents

financial reports

announcements & circulars

company presentation

corporate governance

stock information

ir contacts

email subscription

announcements & circulars

the announcement begins in december 2019

form of proxy for the annual general meeting 2020-04-21
(1) proposed granting of general mandates to repurchase shares and to issue new shares; (2) proposed adoption of post-ipo share option scheme; (3) proposed re-election of the retiring directors; (4) proposed re-appointment of auditors; and(5) notice of annual general meeting 2020-04-21
2019 annual report 2020-04-21
voluntary announcement - jiangsu alphamab received the safe to proceed letter from the u.s. fda for a phase ii clinical trial of kn046 for nsclc in the united states 2020-04-15
adoption of post-ipo share option scheme 2020-04-14
monthly return of equity issuer on movements in securities for the month ended 31 march 2020 2020-04-03
connected transaction announcement - technology development agreement with suzhou alphamab on process optimization and transfer of kn019, kn026 and kn035 and technology development agreement with suzhou alphamab on process scale-up research of kn052 2020-03-31
annual results announcement for the year ended december 31, 2019 2020-03-31
inside information announcement - collaborative agreement with simcere pharmaceutical and 3d medicines for kn035 and supplemental agreements to the kn035 co-development agreement 2020-03-30
voluntary announcement - collaboration with pfizer on kn026 in combination with ibrance(palbociclib) in her2 breast cancer 2020-03-27